Patients with congestive heart disease can have a significant mortality. Several factors can help identify those patients with good or poor prognosis. Liver function tests are convenient and readily available predictors.
Patient Selection: Patients had cardiomegaly and/or abnormal left ventricular dysfunction.
|
Clinical Features |
Value |
3 Year Survival |
|
age in years |
> 65 years of age |
50% (vs 60% for <=65) |
|
gender |
male |
52% (vs 68% for female) |
|
NYHA functional classification |
I |
100% |
|
|
II |
65% |
|
|
III |
62% |
|
|
IV |
38% |
|
diuretic dosage, as furosemide equivalent |
> 160 mg per day |
43% |
|
etiology for heart disease |
ischemic heart disease |
49% |
|
Laboratory Test |
Value |
3 Year Survival |
|
aspartate transaminase (AST, SGOT) |
> 46 U/L |
34% (vs 60% for <= 46) |
|
bilirubin |
> 1.2 mg/dL |
41% (vs 68% for <= 1.2) |
|
urate in mg/dL |
> 8.4 mg/dL |
47% (vs 69% for <= 8.4) |
|
ALT |
> 46 U/L |
48% (vs 60% for <= 46) |
|
alkaline phosphatase |
> 115 U/L |
49% (vs 66% for <= 115) |
|
GGT |
> 66 U/L |
44% (vs 65% for <= 66) |
Limitations:
• The methodology and reference ranges for AST and bilirubin are not stated and could show interlaboratory variability.
• The presence of concurrent hepatic or other disease could affect both the laboratory test findings as well as prognosis.
Specialty: Cardiology
ICD-10: ,
